AirXpanders Places 4,000th AeroForm Implant

AeroForm

AirXpanders Inc, a medical device company focused on the design, manufacture, sale and distribution of the AeroForm Tissue Expander System, announces the 4,000th commercial worldwide placement of the AeroForm Tissue Expander was recently implanted in a patient for post-mastectomy, two-stage breast reconstruction.

“This is a great accomplishment for our company, and an empowering experience for the patient,” says Frank Grillo, president and CEO of AirXpanders, in a media release. “Since we commercialized our technology in Australia in 2015 and the US in 2017, we have seen rapid adoption of the AeroForm Tissue Expander System.

“With AeroForm, patients have the ability to control their own tissue expansion and preparation for the implantation of a permanent implant for breast reconstruction. The use of AeroForm is easier for the physician compared to traditional saline tissue expanders, and patients appreciate the ability to avoid several needle-sticks after surgery,” he adds.

Laurel Burk, director of marketing for AirXpanders, notes that, “Adoption of our technology continues to gain steam in the US. AeroForm is approved for use in over 200 hospitals and hospital systems in the United States, and over 80 in Australia. New US hospitals and physicians are being added monthly, which is adding to our current revenue growth and laying the foundation for future growth and the opportunity for AeroForm to become the standard of care for tissue expansion in breast reconstruction.”

“During the second and third quarter, we have seen continued progress on our key goals as a newly refocused company,” Grillo continues. “We have completed the restructuring of our sales force in the US, and now every established territory has a dedicated sales representative. Our progress in driving adoption in the US is meeting or exceeding our expectations in each territory, and our focus on expense controls and working capital management continues.

“Consistent with our Q3 results, we are confident that our Q4 results, to be released in January 2019, will show another reduction in cash burn, as well as continued US revenue growth. Our business is on track, adoption is growing, and cash burn is slowing versus prior quarters,” he continues, in the release.

[Source(s): AirXPanders Inc, PR Newswire]